Compass-logo-RGB-outlines.png
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 14, 2024 08:00 ET | Compass Therapeutics
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) --  Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Mural_Logo.jpg
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET | Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Cytokinetics.png
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
May 13, 2024 09:33 ET | Cytokinetics, Incorporated
Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were...
Figure 1. Primary Endpoint Change in pVO2
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
May 13, 2024 09:33 ET | Cytokinetics, Incorporated
Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups Rapid and...
barinthuslogo.jpg
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
May 13, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
Reneo_Update_Inline_RGB_REGISTERED_OTL_GREY_TP.jpg
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
May 13, 2024 07:35 ET | Reneo Pharmaceuticals, Inc.; OnKure, Inc
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
enteralogo.png
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
May 13, 2024 07:00 ET | Entera Bio Ltd.
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today...
Macomics.jpg
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
May 13, 2024 04:00 ET | Macomics Limited
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe...
PBC BioVet
Présentation de PBC BioVet : une nouvelle frontière dans les soins de santé vétérinaires
May 12, 2024 20:05 ET | PBC Biomed Ltd
SHANNON, Irlande, 13 mai 2024 (GLOBE NEWSWIRE) -- PBC Biomed est fier de dévoiler son tout nouveau projet, PBC BioVet, une filiale entièrement dédiée aux soins vétérinaires. Fermement résolu à...